Acumen Pharmaceuticals, Inc.
News
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Globe Newswire NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...\n more…
Brokers Issue Forecasts for Acumen Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ABOS)
Zolmax Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals in a report...\n more…
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $6.00 at UBS Group
Ticker Report Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) had its price target dropped by analysts at UBS Group from $14.00 to $6.00 in a report released on Thursday, Marketbeat Ratings reports. The...\n more…
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) to Post FY2024 Earnings of ($1.01) Per Share, HC Wainwright Forecasts
Ticker Report Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - HC Wainwright boosted their FY2024 earnings per share estimates for Acumen Pharmaceuticals in a report issued on Wednesday, August 14th. HC...\n more…